Zobrazeno 1 - 10
of 303
pro vyhledávání: '"Adam S. Cheifetz"'
Autor:
Marta Vuerich, Na Wang, Jonathon J. Graham, Li Gao, Wei Zhang, Ahmadreza Kalbasi, Lina Zhang, Eva Csizmadia, Jason Hristopoulos, Yun Ma, Efi Kokkotou, Adam S. Cheifetz, Simon C. Robson, Maria Serena Longhi
Publikováno v:
Communications Biology, Vol 5, Iss 1, Pp 1-14 (2022)
Unconjugated bilirubin modulates Th17-cell metabolism in Crohn’s disease by limiting glycolysis and through downregulation of phosphoglycerate-kinase-1 (PGK1) and aldolase-A (ALDOA).
Externí odkaz:
https://doaj.org/article/10ccf70848ef46e185bfb5e604e4241c
A primer on common supplements and dietary measures used by patients with inflammatory bowel disease
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 14 (2023)
Inflammatory bowel disease (IBD) is a chronic disease of the intestines. The pathophysiology of IBD, namely Crohn’s disease and ulcerative colitis, is a complex interplay between environmental, genetic, and immune factors. Physicians and patients o
Externí odkaz:
https://doaj.org/article/915e20fa84274efba960ab8b82d58998
Autor:
Rasika P. Harshe, Anyan Xie, Marta Vuerich, Luiza Abrahão Frank, Barbora Gromova, Haohai Zhang, Rene’ J. Robles, Samiran Mukherjee, Eva Csizmadia, Efi Kokkotou, Adam S. Cheifetz, Alan C. Moss, Satya K. Kota, Simon C. Robson, Maria Serena Longhi
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
CD39 is an ectonucleotidase associated with immunoregulatory function. Here authors show regulation of CD39 expression by an endogenous antisense RNA moiety transcribed from the 3‘ end of CD39/ENTPD1 which when itself is silenced results in amelior
Externí odkaz:
https://doaj.org/article/53270d85737b4225a98e857f58c20b7a
Autor:
Konstantinos Papamichael, Steve Lin, Matthew Moore, Garyfallia Papaioannou, Lindsey Sattler, Adam S. Cheifetz
Publikováno v:
Therapeutic Advances in Chronic Disease, Vol 10 (2019)
Anti-tumor necrosis factor (TNF) therapy has revolutionized the medical treatment of the inflammatory bowel diseases (IBD), Crohn’s disease (CD), and ulcerative colitis. Twenty years ago, infliximab became the first anti-TNF agent approved for IBD.
Externí odkaz:
https://doaj.org/article/b61137ad83fd43f189131f627e400639
A comprehensive pocket guide for clinicians and residents, the Oxford American Handbook of Gastroenterology and Hepatology provides authoritative guidance and up-to-date information on the field. The Handbook gives thorough coverage of both diagnosis
Autor:
Mathilde Barrau, Manon Duprat, Pauline Veyrard, Quentin Tournier, Nicolas Williet, Jean Marc Phelip, Louis Waeckel, Adam S Cheifetz, Konstantinos Papamichael, Xavier Roblin, Stephane Paul
Publikováno v:
Journal of Crohn's and Colitis. 17:633-643
Many patients with inflammatory bowel disease [IBD] are treated with anti-tumour necrosis factor [TNF] therapies, of which infliximab [IFX] is most commonly used. Loss of response [LOR] to anti-TNF therapy due to immunogenic failure accounts for 20%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8f5152920f7fb6bf34bf23b0da08e8b
https://doi.org/10.1093/ecco-jcc/jjac164
https://doi.org/10.1093/ecco-jcc/jjac164
Autor:
Gaurav Syal, Miles P. Sparrow, Fernando Velayos, Adam S. Cheifetz, Shane Devlin, Peter M. Irving, Gilaad G. Kaplan, Laura E. Raffals, Thomas Ullman, Krisztina B. Gecse, Phillip R. Fleshner, Amy L. Lightner, Corey A. Siegel, Gil Y. Melmed
Publikováno v:
Digestive diseases and sciences, 67(10), 4687-4694. Springer New York
Background and Aims: The treatment of chronic pouchitis remains a challenge due to the paucity of high-quality studies. We aimed to provide guidance for clinicians on the appropriateness of medical and surgical treatments in chronic pouchitis. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b92217c983c0a8903a7017c785dc7e2c
http://www.scopus.com/inward/record.url?scp=85122854439&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85122854439&partnerID=8YFLogxK
Publikováno v:
Gastroenterology Clinics of North America. 51:299-317
Reactive therapeutic drug monitoring (TDM) is considered the standard of care for optimizing biologics in inflammatory bowel disease (IBD) including Crohn's disease (CD). Preliminary data show that proactive TDM is associated with positive outcomes i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57a1b9306c86c4369d1dd322765a0025
https://doi.org/10.1016/j.gtc.2021.12.007
https://doi.org/10.1016/j.gtc.2021.12.007
Autor:
Xavier Roblin, Gérard Duru, Konstantinos Papamichael, Adam S. Cheifetz, Sandy Kwiatek, Anne-Emmanuelle Berger, Mathilde Barrau, Louis Waeckel, Stephane Nancey, Stephane Paul
Publikováno v:
Journal of Clinical Medicine; Volume 12; Issue 10; Pages: 3395
Monitoring of anti-drug antibodies in patients on ustekinumab is not routinely recommended in patients with inflammatory bowel disease (IBD) due to low rates of immunogenicity. Aim of study: The purpose of this study was to investigate the relationsh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fba6bd0c6b5c883dcad3d9ae8ab4ff3c
Publikováno v:
Expert Review of Gastroenterology & Hepatology. 16:235-249
Inflammatory bowel disease (IBD) is a chronic, inflammatory condition that involves the intestinal tract, and can also present with extra-intestinal manifestations (EIM). Choosing the right treatment for IBD is often nuanced and decisions can become
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64543660d8daa820f645aa2f5eefad76
https://doi.org/10.1080/17474124.2022.2036122
https://doi.org/10.1080/17474124.2022.2036122